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Background: Patients with pulmonary arterial hypertension (PAH) are treated with vasodilators, including
endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylyl cyclase activators,
and prostacyclin. Despite recent advances in pharmacotherapy for individuals with PAH, morbidity and mortality
rates in this patient population remain unacceptably high. Here, we tested the hypothesis that combination therapy
with two PAH drugs that target distinct biochemical pathways will provide superior efficacy relative to monotherapy
in the rat SU5416 plus hypoxia (SU-Hx) model of severe angioproliferative PAH, which closely mimics the human
condition.
Methods: Male Sprague Dawley rats were injected with a single dose of SU5416, which is a VEGF receptor
antagonist, and exposed to hypobaric hypoxia for three weeks. Rats were subsequently housed at Denver altitude
and treated daily with the PDE-5 inhibitor, tadalafil (TAD), the type A endothelin receptor (ETA) antagonist, ambrisentan
(AMB), or a combination of TAD and AMB for four additional weeks.
Results: Monotherapy with TAD or AMB led to modest reductions in pulmonary arterial pressure (PAP) and right
ventricular (RV) hypertrophy. In contrast, echocardiography and invasive hemodynamic measurements revealed that
combined TAD/AMB nearly completely reversed pulmonary hemodynamic impairment, RV hypertrophy, and RV
functional deficit in SU-Hx rats. Efficacy of TAD/AMB was associated with dramatic reductions in pulmonary vascular
remodeling, including suppression of endothelial cell plexiform lesions, which are common in human PAH.
Conclusions: Combined therapy with two vasodilators that are approved for the treatment of human PAH provides
unprecedented efficacy in the rat SU-Hx preclinical model of severe, angioproliferative PAH.
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Pulmonary arterial hypertension (PAH) is associated with
dramatic structural remodeling of small pulmonary arter-
ies (PAs) [1]. The remodeling process is due to excessive
proliferation of fibroblasts, endothelial cells and smooth
muscle cells, and correlates with vascular inflammation
and adventitial fibrosis. Occlusion of PAs, coupled with* Correspondence: timothy.mckinsey@ucdenver.edu
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unless otherwise stated.aberrant vasoconstriction, causes severe increases in pul-
monary vascular resistance (PVR) and often culminates in
right-sided heart failure. As such, it has been proposed
that anti-proliferative agents should be used in combination
with vasodilators for the treatment of PAH. To address this
hypothesis, a Phase III clinical trial was performed with
the anti-cancer agent imatinib in patients with PAH and
receiving background standard-of-care (SOC) therapy
[2]; current SOC for PAH typically involves the use of
vasodilators, including endothelin receptor antagonists
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tolerance and pulmonary hemodynamics in PAH patients.
However, despite functional improvements, imatinib caused
serious adverse side effects, and thus will not be developed
further for the PAH indication [2]. As such, there remains a
significant unmet medical need with regard to treatment of
PAH in humans.
To model PAH pre-clinically, rodents are often exposed
to chronic hypoxia, which causes pulmonary vasoconstric-
tion and right ventricular (RV) hypertrophy [4,5]. An al-
ternative rodent model is based on administration of the
plant alkyloid, monocrotaline, which is thought to trigger
PAH by altering pulmonary artery endothelial cell func-
tion [6]. Despite their widespread use and utility, neither
model exhibits the obliterative vascular lesions found in
human PAH. A breakthrough in PAH research was pro-
vided by the discovery that combining hypoxia with the
VEGF receptor inhibitor, SU5416, in rats results in pro-
gressive and severe PAH characterized by occlusive neoin-
tima and complex plexiform lesions reminiscent of those
found in lungs of patients with PAH [7,8]. In this model,
which will hereafter be referred to as SU-Hx, rats develop
RV failure and PAH that is directly correlated with the de-
gree of occluded vessels [9].
SOC therapies for PAH have exhibited only minimal
efficacy in the SU-Hx model, which is consistent with
the palliative actions of approved PAH drugs, and the in-
ability of these drugs to significantly prolong lifespan in
PAH patients. For example, the soluble guanylate cyclase
(sGC) agonist riociguat lowered PA pressure (PAP) by
approximately 15% in SU-Hx rats, and the PDE-5 inhibi-
tor, sildenafil, was even less effective in the model [10].
The ERA bosentan modestly reduced RV hypertrophy in
SU-Hx rats, and prevented further increases in RV sys-
tolic pressure (RVSP) when delivered starting on day 10
of a 21-day study [11]. Ex vivo, BQ123, a peptide ERA,
was able to partially block spontaneous vasoconstriction
in blood-perfused lungs excised from SU-Hx rats [9].
We hypothesized that, relative to monotherapy, simul-
taneous use of two FDA-approved PAH drugs that target
distinct but redundant biochemical pathways will pro-
vide superior efficacy in the SU-Hx model. To test this
hypothesis, the PDE-5 inhibitor, tadalafil (TAD) [12,13],
was tested in combination with the type A endothelin
receptor (ETA) antagonist, ambrisentan (AMB) [14,15],
for ability to reverse pre-existing PAH in SU-Hx rats.
The data presented here reveal profound and unparal-




Animal experiments were approved by the Institutional
Animal Care and Use Committee at the University ofColorado Denver. Ten week-old male Sprague Dawley
rats (Charles River Laboratories) were used for all studies.
A single dose of SU5416 (Tocris Bioscience; 20 mg/kg) or
vehicle control (50% DMSO and 50% of a solution con-
taining 0.5% carboxymethylcellulose sodium, 0.9% sodium
chloride, 0.4% Tween-80, 0.9% benzyl alcohol in deion-
ized water) was administered at day zero. Rats receiv-
ing SU5416 and were housed in a hypobaric chamber to
simulate an altitude of 18,000 feet above sea level and cre-
ate a hypoxic environment (10% 02). Normoxic control
rats were maintained in chambers simulating sea level
(21% 02). After three weeks, all animals were transferred
to Denver altitude and treated daily for four weeks by oral
gavage with vehicle (0.5% hydroxypropyl-methyl cellu-
lose), tadalafil (10 mg/kg), ambrisentan (10 mg/kg), or a
combination of tadalafil and ambrisentan (10 mg/kg of
each compound). Tadalafil and ambrisentan were obtained
from Sequoia Research Products.
Hemodynamic analysis
Echocardiographic analyses were performed using aVevo770
(VisualSonics). Animals were anesthetized using 2% isoflur-
ane and their body temperature was maintained at 37°C.
Pulse-wave Doppler of pulmonary outflow was recorded
in the parasternal short-axis view at the level of the aortic
valve. Baseline measurements were obtained one day prior
to placing animals in chambers and serially thereafter. RV
hemodynamics were assessed at end-point and after the
last ultrasound analysis using a pressure-volume system
(Scisense); rats were ventilated with 100% oxygen and 2%
isoflurane (Hallowell). Systemic blood pressure was moni-
tored with another pressure catheter inserted in the fem-
oral artery and steady-state hemodynamics were recorded.
PAP was measured with the same catheter advanced to
the main pulmonary artery; correct placement of the cath-
eter was confirmed by observing a significant rise in dia-
stolic pressure as the catheter moved out of the ventricle.
For data from all in vivo studies, GraphPad Prism software
was used to generate graphs and analyze data. ANOVA
with Bonferroni’s post-test (P < 0.05) was used to deter-
mine statistical differences between groups.
Tissue procurement and analysis
After end-point hemodynamic measurements were ob-
tained, rats were sacrificed by exsanguination. Hepari-
nazed blood was used to measure blood gases (ABL825
Flex, Radiometer). Lungs were flushed with cold saline
and the left lobe was inflated with a mixture of 50:50
cryoprotective embedding medium (OCT) and 30% su-
crose, then cut longitudinally and snap-frozen in a block
containing OCT. For assessment of pulmonary vascular
remodeling, lung sections were stained with hematoxylin
and eosin. Stereological assessment of intima (i.e., oblit-
erative) and media (i.e., thickening) was performed using
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Figure 1 Monotherapy to block PDE-5 or ETA signaling modestly reduces pulmonary pressure and RV hypertrophy. (A) Study design.
Animals received 10 mg/kg tadalafil (TAD) or ambrisentan (AMB) once daily by oral gavage starting after week three. (B–C) Mean pulmonary
arterial pressure (mPAP) and PA pulse pressure (PAPP) were measured invasively at study endpoint. (D) RV hypertrophy was assessed by weighing
ventricular chambers at the time of necropsy, and is expressed as a ratio to LV + septum (S). (E) The gene encoding regulator of calcineurin-1
(RCAN1) is regulated by the nuclear factor of activated T cells (NFAT) transcription factor, which translocates to the nucleus in response
to dephosphorylation by the pro-hypertrophic phosphatase, calcineurin. (F) RCAN1 expression in RV homogenates was detected by
immunoblotting. Calnexin served as a loading control. Values represent mean +/−SEM. *P < 0.05 vs. normoxia; †P < 0.05 vs. SU-Hx + vehicle (Veh).
AMB significantly reduced pulmonary arterial pressure and RV hypertrophy, while TAD was without effect. Neither compound consistently blocked RV
calcineurin signaling.
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Figure 2 (See legend on next page.)
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Figure 2 Combined PDE-5 and ETA inhibition reverses pulmonary hemodynamic impairment and RV hypertrophy in SU-Hx rats.
(A) Study design. Animals received 10 mg/kg each of tadalafil (TAD) and ambrisentan (AMB) once daily by oral gavage starting after week three.
(B) Pulmonary artery acceleration time (PAAT) and velocity time integral (VTI) were quantified using Doppler images. Systolic notching of PA
blood flow in an SU-Hx rat treated with vehicle is indicated. (C and D) PAAT and VTI were significantly reduced in SU-Hx rats compared to
normoxic controls, indicating increased pulmonary arterial pressure. PAAT and VTI were rescued by TAD/AMB treatment. (E–G) M-mode
echocardiographic images revealed increased RV anterior wall thickness in SU-Hx rats, which was dramatically reduced by TAD/AMB treatment. For all
graphs, values represent mean +/−SEM. *P < 0.05 vs. SU-Hx + vehicle (Veh). Normoxia (n = 8); SU-Hx (n = 10); SU-Hx + AMB/TAD (n = 12).
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determined that ~40 histological fields provide ~100 hit-
ting points in intima using a 512 point grid. The structure-
specific hitting points were normalized by grid points
hitting alveolar septa, which should not change in un-
treated vs. treated SU-Hx rats, therefore providing a key
measure of the reference tissue. This provides the volume
density of intima or media in relation to alveolar septa,
which is dimensionless. Stereological assessment was per-
formed with coded slides, which were assigned using a ran-
dom number generator.
Frozen lung sections were fixed with 4% paraformalde-
hyde for 15 minutes prior to staining for von Willebrand
factor (vWF; endothelial cells) and α-smooth muscle
actin (αSMA; smooth muscle cells). Antibodies: anti-
vWF (Abcam, ab6994), Cy3-anti-αSMA (Sigma, C6198),
and FITC-anti-rabbit IgG (Invitrogen, A11034). Vectashield
mounting medium with DAPI (Vector, H-1500) was used
to mount coverslip to slides.
RV was dissected from LV by cutting along the septum
and the outer wall of the LV and weighed. Fifty milli-
gram biopsies of RV free wall were flash-frozen in liquid
nitrogen for biochemical analysis. Protein lysates were
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Figure 3 Combined PDE-5 and ETA inhibition suppresses pulmonary h
(mPAP) and PA pulse pressure (PAPP) were measured invasively at stud
was significantly increased by TAD/AMB. Values in all groups are highe
pressure-volume analyses.300 mM NaCl and protease/phosphatase inhibitor cock-
tail (Thermo Fisher) using a Bullet Blender homogenizer
(Next Advance). Proteins were resolved by SDS-PAGE,
transferred to nitrocellulose membranes (BioRad) and
probed with antibodies for RCAN-1 [17] or calnexin
(Santa Cruz Biotechnology, sc-11397). Proteins were de-
tected using a SuperSignal West Pico chemilumines-
cence system (Thermo Scientific) and a FluorChem HD2
imager (Alpha Innotech).
Results and discussion
Monotherapy to inhibit PDE-5 or ETA signaling modestly
reduces PAH and RV hypertrophy in SU-Hx rats
Adult male Sprague Dawley (SD) rats were given a single
injection of SU5416 and subsequently housed in a hypo-
baric chamber to simulate an altitude of 18,000 feet
above sea level and create a hypoxic environment (10% 02)
(Figure 1A). Normoxic control rats were maintained in
chambers simulating sea level (21% 02). After three weeks,
all animals were transferred to Denver altitude and treated
daily (QD) by oral gavage (PO) with TAD, AMB or vehicle
control for an additional four weeks.
Invasive hemodynamic measurements were obtained
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incompletely (Figure 1B). AMB also lowered PA pulse
pressure (PAPP), suggesting that the compound in-
creased arterial compliance in the lungs of SU-Hx rats
(Figure 1C). Consistent with the hemodynamic measure-
ments, RV hypertrophy was modestly suppressed by
AMB monotherapy, but was unaffected by TAD treat-
ment (Figure 1D).
Calcineurin stimulates cardiac hypertrophy by dephos-
phorylating the pro-hypertrophic transcription factor,
nuclear factor of activated T cells (NFAT). Upon dephos-
phorylation, NFAT translocates to the nucleus where it
drives expression of genes that govern the hypertrophic
response. In the heart, calcineurin activity can be moni-
tored indirectly by assessing expression of RCAN1 (regu-














































































n = 8 n = 10 n = 12
A
Figure 4 Combined PDE-5 and ETA inhibition improves RV function in
study endpoint. Representative RV pressure-volume loops are shown. The i
rats was completely blocked by combined TAD/AMB treatment. (D) Pulmo
lowered by TAD/AMB. (E) RV systolic function, based on ejection fraction (E
lower in SU-Hx rats, although the decrease was not statistically significant.harbors 15 NFAT binding sites (Figure 1E) [18]. As shown
in Figure 1F, calcineurin activity (as measured by RCAN1
expression) was dramatically elevated in RVs of SU-Hx
rats and was not significantly altered by TAD or AMB
treatment, which is consistent with the minimal effects of
these compounds on RV hypertrophy (Figure 1D).
Combined PDE-5 and ETA inhibition reverses pulmonary
hemodynamic impairment and RV hypertrophy in SU-Hx
rats
We next sought to determine whether simultaneously tar-
geting PDE-5 and ETA would provide superior efficacy
over monotherapy with either compound. For these stud-
ies, the ability of combined TAD/AMB to reverse pre-
existing PAH and RV hypertrophy was assessed. Baseline
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SU-Hx rats. (A) Invasive pressure-volume analyses were performed at
ncrease in RV end-systolic (B) and end-diastolic pressure (C) in SU-Hx
nary vascular resistance, calculated based on cardiac output, was
F), was normalized by TAD/AMB. (F) RV cardiac output trended
*P < 0.05 vs. normoxia.
Cavasin et al. Journal of Translational Medicine 2014, 12:314 Page 7 of 10
http://www.translational-medicine.com/content/12/1/314exposing male SD rats to SU5416 and three weeks of hyp-
oxia, as described above. As indicated in Figure 2A, serial
echocardiography was performed to assess disease pro-
gression and effects of dual PDE-5/ETA inhibition.
At three weeks, immediately prior to TAD/AMB treat-
ment, SU-Hx rats exhibited reduced pulmonary artery ac-
celeration time (PAAT) and velocity time integral (VTI).
Remarkably, both parameters of PA blood flow were dra-
matically reversed by TAD/AMB treatment (Figure 2B–D).
Reduced pulmonary vascular compliance often causes
transient cessation of forward PA blood flow during
systole, which is detected by Doppler as a “notch” in the
signal. Systolic notching was readily detected in SU-Hx
rats, but was absent in animals treated with TAD/AMB
(Figure 2B). Consistent with the apparent reduction in
PAP in TAD/AMB-treated animals, analysis of M-mode
echocardiographic images of the heart revealed a signifi-
cant regression in RV wall thickness upon dual PDE-5/
ETA inhibition (Figure 2E–G).
Combined PDE-5 and ETA inhibition suppresses PAH and
improves RV function in SU-Hx rats
Invasive hemodynamic measurements obtained at study
endpoint revealed that combined TAD/AMB treatment
completely normalized PAP (Figure 3A and B). Reduced
PAP was associated with increased arterial oxygen partial
pressure (Figure 3C), which is likely due to enhanced ef-
ficiency of gas exchange between alveoli and arterioles
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Figure 5 Combined PDE-5 and ETA inhibition blocks RV hypertrophy
determined by comparing weights of RV vs. LV + septum (S) (A) or RV mas
AMB treatment. (C) LV hypertrophy was not observed in the model. *P < 0.
revealed normalization of RCAN1 expression in RVs of animals treated with
served as a loading control. (E) Elevated RCAN1 expression was observed iPressure-volume analyses indicated highly elevated end-
systolic and diastolic pressures in RVs of SU-Hx rats, which
were reversed by TAD/AMB treatment (Figure 4A–C).
Pressure-volume data also demonstrated that TAD/AMB
reduced pulmonary vascular resistance (PVR) and im-
proved RV ejection fraction (Figure 4D and E). RV cardiac
output trended lower in SU-Hx rats, although the de-
crease was not statistically significant (Figure 4F).
In agreement with ultrasound data, RV hypertrophy in
SU-Hx rats was dramatically reduced by TAD/AMB treat-
ment (Figure 5A and B); LV mass was not altered in SU-Hx
rats (Figure 5C). Suppression of hypertrophy was associated
with reduced pro-hypertrophic calcineurin signaling in
the RV, as evidenced by inhibition of expression of RCAN1
(Figure 5D). Interestingly, despite that absence of LV hyper-
trophy, RCAN1 expression was elevated in the LVs of
some SU-Hx rats (Figure 5E).
Combined PDE-5 and ETA inhibition blocks pathological
pulmonary vascular remodeling in SU-Hx rats
A hallmark of the rat SU-Hx model is severe pulmonary
vascular remodeling. Compared to normoxic controls,
pulmonary arteries of SU-Hx rats were muscularized
and often severely occluded (Figure 6A and B). Classical
plexiform lesions were also observed in SU-Hx lungs
(Figure 6B). Notably, arterial remodeling was dramatic-
ally reduced in TAD/AMB-treated rats (Figure 6C–E),
suggesting that efficacy of this drug combination is due, in
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05 vs. normoxia; †P < 0.05 vs. SU-Hx + vehicle (D) Immunoblotting
TAD/AMB, indicating suppression of calcineurin signaling. Calnexin
n LVs of some SU-Hx rats.
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Figure 6 (See legend on next page.)
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Figure 6 Combined PDE-5 and ETA inhibition blocks pathological pulmonary vascular remodeling in SU-Hx rats. Images of a normoxic
control lung (A), severely hypertensive lung in SU-Hx rats (B), and a lung from an SU-Hx animal treated with TAD/AMB for four weeks (C). Note
that the SU-Hx lungs have marked muscularization of a pulmonary artery (PA, arrowheads), alongside a bronchiole (b), with several occlusive
lesions located within the alveolar unit (arrows). TAD/AMB treatment led to normalization of pulmonary arteries, both at the bronchiolar level (b)
as well as in intra-alveolar compartment (arrows), similar to the pulmonary artery morphology (arrows) seen in control lungs. High magnification
images of the boxed areas are shown in the lower panels. In addition, in (B) the lower panel shows a classical plexiform-like lesion in a vehicle
treated SU-Hx rat. This image was taken from a different slide. pl, visceral pleura; magnification bar =50 μm. Intimal occlusion (D) and medial
thickening (E) in SU-Hx rats was reduced by TAD/AMB treatment. Values represent mean +/−SEM. *P < 0.05 vs. normoxia. †P < 0.05 vs. SU-Hx + vehicle.
(F) Representative images of lung arterioles stained for von Willebrand factor (vWF; endothelial cell marker) and alpha smooth muscle actin
(αSMA; smooth muscle cell marker). Images are overlaid with DAPI-stained nuclei; magnification bar =10 μm. Vessels from SU-Hx rats exhibited
expansion of smooth muscle and endothelial cells, which was reduced by TAD/AMB treatment.
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body staining of lung sections revealed muscularization
and endothelial cell expansion in pulmonary arterioles in
SU-Hx rats, and this vascular remodeling was reduced by
TAD/AMB treatment (Figure 6F).
Conclusions
Morbidity and mortality rates for individuals with PAH
remain unacceptably high, underscoring the need for
additional therapeutic options [19]. In the current study,
monotherapy with 10 mg/kg tadalafil failed to reduce
PAP or RV hypertrophy in the rat SU5416 plus hypoxia
model of PH, while the same dose of ambrisentan was
mildly efficacious. In sharp contrast, combined treatment
with tadalafil and ambrisentan (10 mg/kg each), starting
when SU-Hx rats had pre-existing PH and RV hyper-
trophy, dramatically reversed multiple disease endpoints
in the lung and right side of the heart. The findings under-
score the promise of combinatorial therapy for PAH based
on simultaneous targeting of redundant signaling effec-
tors, PDE-5 and ETA, which serve crucial roles in the
pathogenesis of PAH.
AMBITION is a Phase III clinical trial designed to
assess whether treatment with a combination of TAD
and AMB provides superior efficacy over monotherapy
in newly diagnosed patients with PAH [20]; prelimin-
ary findings from the study were recently announced
at the European Respiratory Society meeting in Munich,
Germany. Participants in the trial include patients with
idiopathic pulmonary arterial hypertension (i.e., PAH or
World Health Organization classified Group I PH), as well
as individuals with PH due to insults such as structural
lung disease, toxin exposure and HIV infection. Based
on data presented here, it will be particularly enlight-
ening to determine whether TAD/AMB is efficacious in
severe, angioobliterative disease. Additionally, a compari-
son of AMBITION data with our results will provide an
unprecedented opportunity to address the predictive value
of the SU-Hx rat model with regard to translating re-
sults to the clinical setting. Such comparisons could have
a profound impact on the success rate of future drugdiscovery efforts with experimental compounds for PAH,
such as inhibitors of leukotriene B4 biosynthesis [21].
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